Table 3E.
Twenty new disease group-specific and 12 shared (more than 4 groups of diseases) Mφ reprogramming pathways have been identified in eight groups of 34 diseases and tumors.
| A. Specific pathways (upregulated except #; unique for each group of diseases) | |
| Autoimmune diseases | Role of JAK1 and JAK3 in γc Cytokine Signaling |
| CNTF Signaling | |
| Thrombopoietin Signaling | |
| EGF Signaling | |
| GM-CSF Signaling | |
| Cardiovascular diseases | IL-17A Signaling* |
| NRF2-Mediated Oxidative Stress Response | |
| Parkinson's Signaling | |
| Digestive inflammatory disease | VDR/RXR Activation# |
| FXR/RXR Activation# | |
| Infection disease | Cyclins and Cell Cycle Regulation |
| Cell Cycle Regulation by BTG Family Proteins | |
| Estrogen-mediated S-phase Entry | |
| Role of CHK Proteins in Cell Cycle Checkpoint Control | |
| Metabolic diseases | Notch Signaling |
| Respiratory disease | Adrenomedullin signaling pathway |
| Digestive tumors | Oncostatin M Signaling |
| Cancer Drug Resistance By Drug Efflux (#, downregulated) | |
| Other tumors | IL-15 Production |
| Role of PKR in Interferon Induction and Response | |
| B. Shared pathways (upregulated and shared by more than four major disease groups) | |
| Altered T Cell and B Cell Signaling in Autoimmune Disease | |
| Differential Regulation of Cytokine Production in Macrophages and T Heiper Cells by IL-17A and IL-17F | |
| Neuroinflammation Signaling Pathway | |
| Graft-vs.-Host Disease Signaling | |
| IL-10 Signaling | |
| Role of Cytokines in Mediating Communication between Immune Cells | |
| Communication between Innate and Adaptive Immune Cells | |
| Role of Hypercytokinemia/Hyperchemokinemia in the Pathogenesis of Disease | |
| FLT3 Signaling in Hematopoietic Progenitor Cells | |
| ERK/MAPK Signaling | |
| JAK/Stat Signaling | |
| Role of JAK1, JAK2 and TYK2 in Interferon Signaling | |
*
Some of the pathway names were simplified to avoid potential confusion.